Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

5.03USD
3:59pm EST
Change (% chg)

$0.02 (+0.40%)
Prev Close
$5.01
Open
$4.90
Day's High
$5.11
Day's Low
$4.87
Volume
182,720
Avg. Vol
201,608
52-wk High
$6.30
52-wk Low
$3.64

Summary

Name Age Since Current Position

Avtar Dhillon

57 2011 Non-Executive Chairman of the Board

Jong Kim

49 2009 President, Chief Executive Officer, Director

Peter Kies

54 2002 Chief Financial Officer

Niranjan Sardesai

50 2012 Chief Operating Officer

Laurent Humeau

2018 Chief Scientific Officer

Mark Bagarazzi

57 2010 Chief Medical Officer

David Weiner

62 2016 Director

Simon Benito

73 2003 Independent Director

Angel Cabrera

50 2012 Independent Director

Morton Collins

82 2009 Independent Director

Adel Mahmoud

76 2012 Independent Director

Wendy Yarno

63 2017 Independent Director

Biographies

Name Description

Avtar Dhillon

Dr. Avtar S. Dhillon is the Non-Executive Chairman of the Board of Inovio Pharmaceuticals Inc. Dr. Dhillon is the President and Chief Executive Officer, and as a director, in October 2001, served as our Chairman and President from June 1, 2009 to October 6, 2009, and served as Executive Chairman until August 1, 2011. Effective August 1, 2011, Dr. Dhillon became our Non-Executive Chairman, transitioning from Executive Chairman. Dr. Dhillon qualifies to serve on our Board as he brings to our Board his prior experience in senior management positions with us and with our products and assets, extensive public company governance, financing and capital markets experience and significant industry expertise and contacts. Prior to joining us, Dr. Dhillon was engaged by MDS Capital Corp. (subsequently Lumira Capital Corp.), one of North America’s leading healthcare venture capital organizations, as a consultant in July 1998, and subsequently became Investment Manager in August 1999 and Vice President in 2000. In July 1989, Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years. From March 1997 to July 1998, Dr. Dhillon served as consultant to multiple biotech companies, including Cardiome Pharmaceuticals, a biotechnology company listed on the NASDAQ Capital Markets. Dr. Dhillon has a Bachelor of Science, honors degree in physiology and M.D. degree from the University of British Columbia. Dr. Dhillon is also the Non-Executive Chairman of Oncosec Medical, Inc., Arch Therapeutics Inc., Stevia First Corp., and Emerald Health Therapeutics, Inc.

Jong Kim

Dr. Jong Joseph Kim is the President, Chief Executive Officer, Director of Inovio Pharmaceuticals Inc. Dr. Kimjoined the Company as Chief Executive Officer and a director on June 1, 2009 and also became President on October 6, 2009. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. Prior to joining VGX, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck. These products include FDA-approved vaccines for Hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 100 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. In 2002, Dr. Kim was named as one of the world’s top 100 young innovators by Technology Review magazine and as one of the “40 under 40” by the Philadelphia Business Journal, which highlights the most dynamic professionals who are under 40 years of age in the region. Dr. Kim was also selected on the list of the “50 Most Influential Men” in the October 2003 and in the October 2006 Power Issue” of Details Magazine. In 2004, Dr. Kim and VGX were selected as one of 30 Technology Pioneers by the World Economic Forum. Furthermore, Dr. Kim was featured in the “Who’s Next 2005” issue of Newsweek International, which included a group of 10 leaders, scientists, and executives at the forefront of change and impact in the world. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.

Peter Kies

Mr. Peter D. Kies is the Chief Financial Officer of Inovio Pharmaceuticals Inc., since June 2002. For the 15 years prior to joining tot the company, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from initial public offering to profitability. From May 1996 until joining tot the company, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.

Niranjan Sardesai

Dr. Niranjan Y. Sardesai, Ph.D., is the Chief Operating Officer of Inovio Pharmaceuticals, Inc., since January 4, 2012. Dr. Sardesai joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. In January 2012, Dr. Sardesai was named Chief Operating Officer. In his expanded role, Dr. Sardesai is responsible for Corporate Development and Business Development for the company as well as the company’s product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He serves as the PI on an NIAID/NIH funded contract for the development of HIV vaccines and an MVI funded program for malaria vaccine development. Prior to VGX, Dr. Sardesai was the founder and President of NVision Consulting Inc., a strategy consulting firm focused on entrepreneurial life sciences companies, and he served as Director R&D at Fujirebio Diagnostics, Inc. At Fujirebio, Dr. Sardesai oversaw R&D and expansion of the oncology portfolio. Products developed under his leadership include new-to-the-world tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer. He has authored 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents. Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He completed fellowships at Scripps Research Institute and Massachusetts Institute of Technology. Dr. Sardesai received his bachelors and masters in Chemistry from the Indian Institute of Technology, Bombay.

Laurent Humeau

Dr. Laurent Humeau is Chief Scientific Officer of the Company. Dr. Laurent who joined Inovio in 2014, serves an integral role in advancing Inovio's portfolio of immunotherapies and vaccines covering multiple therapeutic cancers and infections, supporting clinical study opportunities, and fostering collaborations with academic partners. He provides the technical and strategic leadership for Inovio's highly productive R&D group whose activities include: preclinical development of immunotherapy and vaccine candidates, immunology and immune monitoring approaches, method development, product characterization, and analytical development. Under Dr. Humeau's leadership, Inovio's R&D group along with its collaborators published more than 100 peer-reviewed preclinical and clinical publications and dozens of new patent filings as well as receiving over $150 million in non-dilutive grants and contracts from CEPI, DARPA, NIH, and the Gates Foundation in support of Inovio's platform and vaccine development.

Mark Bagarazzi

Dr. Mark L. Bagarazzi is the Chief Medical Officer of Inovio Pharmaceuticals Inc., since January 5, 2010. Prior to joining Inovio, Dr. Bagarazzi was Director of Worldwide Regulatory Affairs for vaccines and biologics at Merck & Co. Prior to joining Inovio, Dr. Bagarazzi was Director of Worldwide Regulatory Affairs for vaccines and biologics at Merck & Co. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. Dr. Bagarazzi was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also successfully led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and is a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania School of Medicine. Previously, he was a guest lecturer at Johns Hopkins University. Dr. Bagarazzi holds several patents and has co-authored dozens of scientific papers, focused on the subject of DNA vaccines, that have been published in peer-reviewed medical journals. Dr. Bagarazzi holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from the University of Medicine and Dentistry of New Jersey.

David Weiner

Dr. David B. Weiner Ph.D., is the Director of Inovio Pharmaceuticals Inc. Dr. Weiner recently joined The Wistar Institute, the nation’s first independent biomedical research institute, NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research, as Executive Vice President, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research. On March 1, Dr. Weiner retired as Emeritus Professor, Department of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine. Dr. Weiner is a world-renowned leader in immunology as well as gene vaccines and immunotherapy. He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor of more than 100 issued and pending US patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. Dr. Weiner was the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy. David Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati. and a B.S. in biology from SUNY at Stony Brook in Stony Brook, N.Y.

Simon Benito

Mr. Simon X. Benito is an Independent Director of Inovio Pharmaceuticals Inc., since December 18, 2003. Prior to his retirement, Mr. Benito had a career serving several multinational corporations in senior executive positions, including 25 years at Merck & Co, Inc. Mr. Benito positions included Senior Vice President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.

Angel Cabrera

Dr. Angel Cabrera, Ph.D., is an Independent Director of Inovio Pharmaceuticals, Inc., since June 15, 2012. Dr. Cabrera is currently President of George Mason University, the largest public university in Virginia. Previously he was president of the Thunderbird School of Global Management, widely regarded as the world’s leading graduate school of international business. Prior to Thunderbird, Cabrera served as Dean of IE Business School in Madrid, one of Europe’s top business schools. Prior to IE he was a change management consultant with Accenture. Dr. Cabrera earned his Ph.D. and M.S. in psychology and cognitive science from the Georgia Institute of Technology—which he attended as a Fulbright Scholar—and his B.S. and M.S. in computer and electrical engineering from Madrid’s Polytechnic University. He has received several leadership recognitions from the World Economic Forum, the Aspen Institute, the Washington Business Journal, Business Week and the Financial Times. His extensive publishing in fields ranging from learning technology to psychology, management and higher education includes a recent book, “Being Global: How to Think, Act and Lead in a Transformed World.” Dr. Cabrera is an advocate of corporate social responsibility and managerial professionalism. Dr. Cabrera currently serves as member of the Board of PetSmart (PETM).

Morton Collins

Dr. Morton Collins, Ph.D., is an Independent Director of Inovio Pharmaceuticals Inc . Dr. Collins was previously a director of VGX from June 2008 to June 2009. Dr. Collins has been the Managing Partner of Battelle Ventures, which he founded, since August 2003. For the past 40 years, Dr. Collins has acquired broad experience in venture capital funding of early-stage high-technology companies as a founder and managing partner of five different funds, Data Science Ventures I, II, III, and IV and Cardinal Partners. Dr. Collins chaired President Reagan’s Task Force on Innovation and Entrepreneurship and served as a technology policy advisor to President George H. W. Bush. He is a former President, Director and Chairman of the National Venture Capital Association, and currently serves as Director to Kopin Corporation and several private companies. Dr. Collins holds a B.S. in Engineering from the University of Delaware, and his M.A. and Doctorate degrees in Engineering from Princeton University.

Adel Mahmoud

Dr. Adel A. F. Mahmoud, M.D., Ph.D., is an Independent Director of Inovio Pharmaceuticals Inc., since March 26, 2012. Dr. Mahmoud’s academic pursuits focused on investigations of the biology and function of eosinophils particularly in host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006, including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. Dr. Mahmoud’s leadership in setting strategies for Global Health shaped the agenda of the Forum on Microbial Threats of the Institute of Medicine in recent years by tackling topical issues such as biological threats and bioterrorism; SARS; Pandemic Flu and others. Dr. Mahmoud is an active contributor to scientific literature and authored and edited several textbooks and reports. Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London, School of Hygiene and Tropical Medicine in 1971. Dr. Mahmoud was elected to membership of the American Society for Clinical Investigation in 1978, the Association of American Physicians in 1980 and the Institute of Medicine of the National Academy of Sciences in 1987. Dr. Mahmoud received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983, and the Squibb Award of the Infectious Diseases Society of America in 1984. Dr. Mahmoud is a fellow of the American College of Physicians. He served on the National Advisory Allergy and Infectious Diseases Council and is a past president of the Central Society for Clinical Research and the International Society for Infectious Diseases. He currently serves as member of the Board of IAVI and as Chair of the Board of IVI in Seoul.

Wendy Yarno

Ms. Wendy L. Yarno is an Independent Director of Inovio Pharmaceuticals Inc. Ms. Yarno retired in September 2008 from Merck & Co., Inc. following a 26-year career there in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer before she retired. Prior to this role, she served as General Manager for Merck’s Cardiovascular/Metabolic United States Business Unit and as Senior Vice President, Human Resources. From 2010 to 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno currently serves on the boards of directors of the biopharmaceuticals companies Alder BioPharmaceuticals, Inc. and MyoKardia, Inc., and Aratana Therapeutics, Inc., a pet therapeutics company. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., a medical device company, from 2002 until January 2017 when St. Jude Medical was acquired by Abbott Laboratories; Medivation, Inc., a biopharmaceutical company, from April 2013 until September 2016 when Medivation was acquired by Pfizer Inc.; and Durata Therapeutics, Inc., a pharmaceutical company, from August 2014 until November 2014 when Durata was acquired by Actavis plc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A from Temple University.

Basic Compensation

Name Fiscal Year Total

Avtar Dhillon

208,004

Jong Kim

4,389,270

Peter Kies

1,447,390

Niranjan Sardesai

1,480,620

Laurent Humeau

--

Mark Bagarazzi

1,444,720

David Weiner

549,754

Simon Benito

189,004

Angel Cabrera

176,504

Morton Collins

188,004

Adel Mahmoud

170,004

Wendy Yarno

111,064
As Of  30 Dec 2017

Options Compensation